Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | AVPR1B | P47901 | 12/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9259613 | 0.90 | HRH3 (0.40) | HRH3AVPR1BADRB2ADRB1 | |
| SCHEMBL9255567 | 0.85 | HRH3 (0.40) | HRH3AVPR1BNPC1RAB9AADRB2 | |
| SCHEMBL9248511 | 0.85 | HRH3 (0.42) | HRH3AVPR1BNPC1RAB9AAPP | |
| SCHEMBL9251212 | 0.85 | HRH3 (0.42) | HRH3AVPR1BNPC1RAB9AAPP | |
| SCHEMBL9257434 | 0.83 | NPC1 (0.42) | HRH3NPC1RAB9A | |
| SCHEMBL9259034 | 0.83 | NPC1 (0.42) | HRH3NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL9256062 | 0.82 | NPC1 (0.41) | HRH3NPC1RAB9A | |
| SCHEMBL9257933 | 0.82 | HRH3 (0.39) | HRH3AVPR1BNPC1RAB9A | |
| SCHEMBL9250844 | 0.82 | HRH3 (0.42) | HRH3AVPR1BNPC1RAB9AAPP | |
| SCHEMBL9259602 | 0.81 | HRH3 (0.40) | HRH3AVPR1BNPC1RAB9APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5463071-A | Tetrazole derivatives; useful for inhibiting undesirable cell aggregation | DR. KARL THOMAE GMBH (DE) | 1995-10-31 | — | — | US | disclosed |